AstraZeneca Korea announced today that its Tagrisso in combination with platinum-based chemotherapy has been approved for the first-line treatment of EGFR-mutated non-small cell lung cancer.

The approval marks the first time a combination therapy has been approved for the first-line treatment of EGFR-mutated lung cancer.

The approval is based on the Phase III FLAURA2 trial in 557 patients with locally advanced or metastatic NSCLC who had received no prior systemic therapy and were positive for EGFR exon 19 deletion or exon 21 mutation. The study evaluated the efficacy and safety of the Tagrisso combination therapy versus Tagrisso monotherapy.

Results showed that T